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Neither Out Far Nor In Deep 
The people along the sand 
All turn and look one way. 
They turn their back on the land. 
They look at the sea all day. 
As long as it takes to pass 
A ship keeps raising its hull*. 
The wetter ground like glass 
Reflects a standing gull. 
The land may vary more; 
But whatever the truth may be-- 
The water comes ashore, 
And the people look at the sea. 
They cannot look out far. 
They cannot look in deep. 
But when was that ever a bar 
To any watch they keep? 
Robert Frost 
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I. INTRODUCTION 
1. Definition of problem 
In the neonate, within the first five to seven 
days of life, the serum bilirubin may increase from less 
than one mg.% in cord blood to values as high as 2$ 
and then spontaneously remit. In an adult, such a rapid 
rise would indicate the need for investigation ©f hepatic 
function. In the neonatal age group, this phenomenon is 
viewed as a normal variation. Despite the prevalence of 
neonatal jaundice, both "physiologic" and as a complica¬ 
tion of other medical and maternal problems, the exact 
causes and long-term effects of hyperbilirubinemia are 
incompletely understood. This investigation has examined 
one cause of neonatal jaundice, the enterohepatic circu¬ 
lation of bilirubin. To show the importance of this fac¬ 
tor, current concepts of neonatal bilirubin metabolism 
will be reviewed. On the basis of this review, the 
rationale for and effectiveness of the various treatment 
modalities for hyperbilirubinemia will be examined. 
Finally, a brief survey of the developmental consequences 
of neonatal jaundice will be made. By defining factors 
in the neonatal period which lead to significant jaundice, 
developmental studies should help focus further research 
into the causes of hyperbilirubinemia. 
. 
-■ 





2. Neonatal bilirubin metabolism 
While liver enzyme immaturity and increased hemol¬ 
ysis are the usual explanations for neonatal hyperbilirubi¬ 
nemia, these concepts must be better defined, and other fac¬ 
tors included to account for the rapid rise and fall of 
serum bilirubin values in some infants. As outlined in 
diagrams 1 and 2, each step in fetal and neonatal bilirubin 
metabolism will be reviewed, and the importance of its 
contribution to neonatal jaundice assessed, 
a) Bilirubin metaoolism in utero 
The two primary sites of excretion of bilirubin 
for the fetus are the amniotic fluid and the placenta. 
While some studies have suggested that the fetal liver’s 
ability to handle bilirubin may be induced by high circu¬ 
lating levels of unconjugated bilirubin, it plays a small 
role in normal fetal bilirubin excretion. (1,2) 
The route along which bile pigments pass from the 
fetus to the amniotic fluid is not known. (3) Possible 
routes which have been investigated include the gastroin¬ 
testinal tract, skin, tracheobronchial tree, and kidney. 
Cherry et al, collected data concerning the concentration 
of protein in amniotic fluid versus that in the umbilical 
cord. (4) They suggested on the basis of a gradient 
between these two compartments that a bilirubin gradient 
between fetal plasma and amniotic fluid might be estab¬ 
lished which favored the transfer of unconjugated 
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bilirubin across partitioning membranes without its 
albumin carrier. Such a gradient might occur across the 
fetal surface ©f the placenta, cord tissue, or fetal skin. 
Such an equilibrium would also explain the observation 
that in normal, non-immunized pregnancies, there is a 
drop in both bilirubin and protein concentrations in the 
amniotic fluid late in pregnancy. (3) In order to test 
this gradient hypothesis, 1500 mg, of albumin was injected 
into the amniotie fluid of three females. Subsequent 
amniocentesis revealed a significant passage of free bill™ 
rubin from the fetus into the amniotie fluid, a finding 
which supported their theory. 
Another suggestion made by some authors was that 
the tracheobronchial tree contributes to the excretion ©f 
bilirubin into the amniotie fluid. (5) Recent animal 
studies by Goodlin et al, have shown convincingly, at 
least in the goat and sheep, that tracheal fluid has no 
significant excretory functions. (6) 
A third possible excretory route of bilirubin 
into the amniotie fluid is the fetal kidney, (7) While 
fetal urine definitely contributes to the amniotie fluid, 
as indicated by the oligohydramnios which accompanies 
renal agenesis, it probably represents only a conduit 
system for the renal filtrate. (7,8) Although unconjugated 
bilirubin has been demonstrated in the urine of newborns (7), 
1 v . • . : ■ . ; . . ; 
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4 
neonatal renal excretory ability is limited by the low 
fetal glomerular filtration rate, (8) 
The major excretory route for fetal bilirubin is 
the placenta, (2) The equilibrium across the placenta is 
similar to that between amniotic fluid and fetus in that 
the bilirubin crosses into the mother's circulation with¬ 
out its albumin carrier, (4) It appears to be conjugation, 
not protein binding, which impedes bilirubin clearance by 
the placenta. Experiments involving bilirubin clearance 
in animals, primarily monkeys, suggest that there is no 
significant transfer of conjugated bilirubin across the 
placenta, (5»9) However, because of the marked degree ©f 
deconjugation of fetal bilirubin, the placenta can usually 
handle the fetal bilirubin load. H^-labelled. bilirubin 
studies of dogs and monkeys have shown that while there 
is marked species variation, the combined rate of placen¬ 
tal and fetal hepatic excretion of label was only slightly 
lower than normal adult hepatic values. (10) These data 
are supported in the human by the finding that cord bili¬ 
rubin levels have little predictive value in neonatal 
jaundice unless there has been increased hemolysis in 
utero. (11) Thus, as long as the major part of the bili¬ 
rubin load in utero is unconjugated, and there is no 
marked increase in bilirubin load (e,g,, hemolysis), there 
should be no build-up of bilirubin in the fetus. 
■Jr .;c- . ' 
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to) Neonatal toilirutoin load 
Many authors have noted that the toilirutoin load 
generated secondary to hemolysis of neonatal red tolood 
cells cannot adequately account for the magnitude nor the 
speed of the rise in serum toilirutoin in the neonatal 
period. (12-16) First investigators of this problem 
examined the relationship between the hematocrit or total 
RBC mass and the degree of hyperbilirubinemia which devel¬ 
ops in neonates. As measured by these parameters, the 
average amount of tolood destruction in groups of jaundiced 
and nonjaundiced infants was essentially the same, (17,18) 
In an effort to examine the phenomenon of RBC turnover 
with a more dynamic tool, RBC survival times were measured. 
While the methods for measuring RBC survival varied, the 
results were all quite similar. In comparing normal new¬ 
borns with adults, most investigators found a decrease of 
up to 33% in RBC survival time in the normal neonate. (1,2, 
15,19-21) A reduced RBC survival time was found in prema¬ 
ture infants when compared with normal newborns, (9,1^) 
These sources differed, however, concerning the ability of 
the shortened RBC survival time to account for the phenome¬ 
non of neonatal jaundice. 
Researchers then turned to an investigation of the 
molecular catabolism of hemoglobin to bilirubin. The prim¬ 
ary area of concern has been the heme oxygenase system. 
This set of exzymes catalyzes the reduction of hemoglobin 
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to bilirubin. In the adult this system is present in 
highest concentration in the spleen, with activity also 
being located in the liver and bone marrow. (9,22) How¬ 
ever, total hepatic activity predominates over splenic 
activity during intrauterine and neonatal life. (23) 
Recent work by Tenhunen et al, has pointed to a two step 
process whereby heme is first transformed to biliverdin 
by microsomal heme oxygenase, (22) The second reduction 
is then coupled with a soluble NADPH-dependent biliverdin 
reductase to form bilirubin. Although experimentation on 
this newly discovered system is incomplete, preliminary 
work indicates that some of the factors correlated with 
hyperbilirubinemia (e.g„, hypoglycemia) also stimulate 
the heme oxygenase, (24) As Thaler points out, current 
evidence suggests that the hormones epinephrine and glu- 
cogon, secreted in response to a falling peripheral glu¬ 
cose level in the first 12 hours of life, stimulate a steep 
rise in the activity of many hepatic enzymes during the 
first post-partum day. (23) Among them is the heme oxy¬ 
genase system. Moreover, in adult rats, bilirubin pro¬ 
duction is increased when the activity of heme oxygenase 
is stimulated without a corresponding increase in RBC 
destruction. (23,25) Thus, infants of diabetic mothers 
may form bilirubin at faster rates than normal newborns, 
(26) The activity of this enzyme system relative to the 
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transferase system may offer a reasonable molecular explan¬ 
ation for neonatal jaundice. A transient increase in 
bilirubin formation secondary to an increase in heme oxy¬ 
genase activity rather than hemolysis is thus an attrac¬ 
tive concept now gaining more attention. 
Administration of labelled hemoglobin precursors has 
also increased understanding of the way in which hemoglobin 
IS 
catabolism affects the bilirubin load. When N -labelled 
glycine is administered to rats, three peaks of labelled 
bilirubin excretion in stool are found, (2?) There are 
two peaks in the first three to five days, the so-called 
"early-labelled bilirubin," These peaks account for about 
15$ of the total label and are thought to be from a variety 
of sources, including by-products of heme synthesis in the 
liver, continuous low-grade production from cytochromes, 
myoglobin, and catalase, and, most importantly, ineffective 
erythropoiesis, The third peak at 40 to 80 days or "late 
labelled bilirubin" coincides with expected red cell sur¬ 
vival, and accounts for approximately 65$ of the label. 
When this experiment is done on human adults, the same pat¬ 
tern is obtained. (9) However, when Vest et ai, injected 
labelled glycine into two normal infants, they found the 
first peak of fecal bilirubin pigment excretion to be 
approximately twice as high in the newborn as in the adult, 
(1) To investigate the non-hemoglobin contribution to this 
early labelled peak, studies using simultaneously 
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administered glycine and aminolevulinic acid (ALA) were 
performed. (27) ALA is a preferential precursor of non¬ 
hemoglobin sources of bile pigment. It was found that the 
newborn appears to be an overproducer of bilirubin from 
both hemoglobin and non-hemoglobin sources. (26) Thus, 
although the bilirubin load from both erythropoietic and 
non-erythropoietic sources is increased in the neonatal 
period, the increase is not sufficient to account for the 
rapid rise and fall seen in neonatal serum bilirubin 
levels. 
c) Bilirubin transport in blood 
Bilirubin is transported in the blood tightly bound 
to albumin. (28-30) In vitro studies have shown that one g. 
of albumin can bind approximately 16 mg, of bilirubin. (28) 
While the newborn's albumin can bind bilirubin (9)# there 
is evidence that the binding capacity is not as great as in 
the adult. (31) As little as 1.5 g* of albumin may be 
available for binding bilirubin in some newborns, (31) 
Odell has pointed out that this decreased binding capacity 
may increase the infant’s susceptibility to bilirubin tox¬ 
icity, and that small changes in pH may alter the binding 
ability of albumin for bilirubin. (30) While the possibil¬ 
ity of increasing the albumin concentration in the blood 
is one means of treatment of neonatal jaundice which has 
been tried in animals (32) and humans (33), its effective¬ 
ness is clearly limited by the amount that can be 
' > • * ;. . ■ .. . : 
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administered before the protein’s osmotic effect disrupts 
the infant’s fluid balance. Moreover, Wong found no bene¬ 
ficial results from albumin therapy, (33) While the abil¬ 
ity of the infant’s albumin t© bind bilirubin is thus a 
factor in his susceptibility to bilirubin toxicity, it is 
not a factor in the rapid rise and fall in serum bilirubin, 
d) Neonatal liver in bilirubin metabolism 
1) Uptake of bilirubim In 19^8, using a clearance 
measurement independent of the original serum bilirubin 
concentration, Fashena calculated that in every instance 
of neonatal hyperbilirubinemia, the velocity constant for 
bilirubin clearance was less than the velocity constant 
for neonates with a normal serum bilirubin, (17) In 1952, 
Obrinsky et al. demonstrated impaired clearance of BSP in 
newborn monkeys and humans, (3^,35) Since the early 1960’s, 
investigators have searched for the molecular means by 
which the hepatocyte can clear bilirubin from the blood. 
In 1966, Odell et al, demonstrated the ability of the liver 
to concentrate bilirubin by infusing adult rats with labelled 
bilirubin and then analyzing various organs for their content 
of label. (36) He found that despite the fact that the kid¬ 
neys receive twice the blood flow of the liver, there was 19 
times more bilirubin in the liver than the kidney. He 
hypothesized that there must therefore be a receptor carrier 
mechanism along the sinusoidal border of the hepatocyte to 
remove the albumin-bound bilirubin from the extra-cellular 
, . .» ■ 
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fluid. Studies over the last four years on animals, using 
subfractionates of the liver, have revealed that infected 
labelled bilirubin was bound by proteins and/or lipids 
contained in liver cytoplasm. Specifically, investigators 
found that once inside the liver, the amount of bilirubin 
in cell sap exceeded the carrying capacity of intracellular 
albumin at least thirty fold, (23) In 1969* Levi et al, 
isolated two proteins, called Y and Z, from the liver cyto¬ 
plasm. (37) They showed that these two proteins account 
for most of the intracellular bilirubin and BSP found after 
infection of these anions in vivo or their addition to 
liver supernatant in vitro. (38) Y was characterized as a 
basic protein which binds bilirubin, BSP, and other anions 
in vitro or in vivo. Z binds bilirubin or BSF when their 
concentrations on Y exceed a critical level. (38) Both 
proteins were found in liver of many mammalian species. 
Attention was then turned to the rhesus monkey, a species 
which manifests physiologic jaundice. It was found that 
Y was virtually absent at birth and attained adult levels 
by approximately the second week of life, Z developed 
prior to birth. (38) Maturation of the Y protein thus 
coincided with maturation of the hepatic uptake of BSP as 
well as amelioration of physiologic jaundice. (35»39) 
These data suggested that the Y and Z proteins represented 
the rate-determining steps in hepatic transport. Moreover, 
phenobarbitone has been shown to increase the concentration 
. 
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of the Y protein. (40) It has therefore been suggested 
that this effect might account partially or completely 
for phenobarbitone’ s beneficial effect on neonatal jaun¬ 
dice (vide infra). However,, this thesis has not been 
demonstrated in humans. 
More recent investigation, however, has raised 
new questions about the roles of these proteins. Compe¬ 
tition studies have shown that neither protein can dis¬ 
lodge bilirubin from its attachment to albumin, (23) 
These findings suggest that the membrane itself may play 
an active role in the uptake process. Selective receptors 
on the plasma membrane of the hepatocyte may mediate the 
uptake of organic anions, while the Y and Z proteins may 
simply distribute non-polar compounds to sites on the 
endoplasmic reticulum where conjugation is accomplished, 
(23) Further study of the hepatocyte*s plasma membrane 
is required before our understanding of the uptake of 
bilirubin can be complete, 
2) Con.iugationi Along with increased hemolysis, 
inability of the hepatocyte to conjugate bilirubin has 
been the factor traditionally singled out as the cause of 
neonatal jaundice. This idea first became popular in 
1958 from the work of Brown and Zuelzer. (41) They found 
that homogenized adult guinea pig livers could conjugate 
bilirubin to bilirubin diglucuronide. However, they were 
unable to demonstrate any conjugating ability in a fetal 
■ 
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or newborn liver. Their results also indicated a ’’gradual 
increase" in activity of glucuronyl transferase during the 
neonatal period. They felt that two enzymes were defi¬ 
cient* glucuronyl transferase (UDPGT)* and uridine-di- 
phospho-glucuronide dehydrogenase (UDPGD). In the same 
year, Lathe and Walker examined three premature human neo¬ 
natal livers (ages 98 hours* 5 minutes, and 65 minutes) 
all within 1,5 to 2,5 hours of autopsy, (42) Their results 
also suggested deficient glucuronide forming enzyme. Other 
histological studies showed that UDPGT was located in the 
smooth endoplasmic reticulum, that the smooth ER was vir¬ 
tually absent at birth, and that phenobarbitone caused an 
increase in the smooth ER coincident with a decrease in 
unconjugated bilirubin, (38) Moreover, by showing impaired 
excretion of substances conjugated by liver in the same way 
as bilirubin (p-aminobenzoic acid, N-acetyl-p-aminophenol), 
investigators again indicated the inadequacy of the glucu- 
ronidating enzymes of the liver. (38) 
However, as more experience was gained by various 
investigators with different species of laboratory animals 
and with the availability of sin assay of UDPGT, it became 
apparent that the deficiency in transferase activity varied 
with both species and investigator, Gartner et al, working 
with liver slices from adult and fetal Wistar rats found 
that both adult and fetal livers had an equal ability for 
r ' ' ry 
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phenol-glucuronide conjugation. (43) They noted that since 
the pattern differed from that observed earlier in the rat 
and guinea pig livers, the pattern was more dependent on 
the species and method than on true transferase activity. 
These findings were corroborated by Dutton et al. who worked 
with Wistar rat liver homogenates. (44) They observed that 
’’though low in early fetuses, glucuronyl transferase activity 
in newborn preparations was as high as in adult males, rising 
to even twice that value in the first four days before fal¬ 
ling below it,” They also pointed to insufficient concen¬ 
tration of uridine-di-phospho-glucuronic acid in the assay 
for UDPGT as an explanation for the anomalously low results 
of other investigators. As these facts became known, more 
data accumulated showing that a decrease in transferase 
activity could not account for the serum bilirubin accumu¬ 
lation in the neonatal period. (12,16,35,38»45) 
Thus, although the ’’functional immaturity” of fetal 
and neonatal liver for conjugation of bile pigment has 
been "amply documented" according to Schmid (46), recent 
evidence has led investigators away from the traditional 
concept of decreased transferase activity as a sole cause 
of neonatal jaundice. Researchers are now looking at steps 
in bilirubin excretion after conjugation for possible expla¬ 
nations of the rapid rise and fall in serum bilirubin. 
3) Excretion% Excretion is one of the least under¬ 
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accepted that in order for bilirubin to be excreted in the 
bile, it must be conjugated with a glucuronide, (16,47) 
This fact was first reported by Schmid in 1956* (48) Using 
chromatographic purification and beta-glucuronidase of 
animal or bacterial origin, he showed that hydrolysis of 
azo-pigment B, always found in bile and urine, resulted 
in its complete conversion to azo-pigment A, While occa¬ 
sional investigators have reported some unconjugated bili¬ 
rubin in bile (49), most researchers feel that these small 
quantities of unconjugated bilirubin are probably produced 
by hydrolysis of the conjugated form during analysis, (47) 
In terms of its overall role in bilirubin metabolism, 
excretion has been shown in animal models to be more effi¬ 
cient in eliminating conjugated than unconjugated bilirubin, 
a fact which suggests that, at least in guinea pigs, con¬ 
jugation and not excretion is the rate-limiting step in 
overall pigment metabolism, (50) However, as Thaler sug¬ 
gests, if hepatic transport, conjugation, and excretion 
of bilirubin are viewed as a single ongoing process, the 
excretory function which is known to require expenditure 
of metabolic energy is likely to be the final rate-limiting 
step. (23) More recent evidence has suggested that, at 
least in newborn monkeys, the clearance of bilirubin 
appears limited by conjugation in the first day of life 
and by excretion thereafter. (51) As in the previously 
discussed hepatic factors in neonatal bilirubin metabolism. 
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an adequate understanding of the excretory function of the 
hepatocyte has not yet been attained, 
4) Vascular changes in the neonatal liver at births 
Several authors have pointed out that the profound circula¬ 
tory changes in the liver at birth offer a reasonable 
explanation for the time curve of neonatal jaundice. (52, 
53) At birth, the pressure in the umbilical vein drops 
from over ten ml. of mercury to zero, and the pressure 
gradient and oxygenation of the portal blood fall rapidly, 
(52) The blood reaching the relatively large left lobe 
of the liver thus switches from highly oxygenated umbili¬ 
cal vein blood to portal venous blood. While this adjust¬ 
ment is taking place, liver function presumably will be 
markedly impaired. Histologic studies have shown shrink¬ 
age of liver cells as well as decreased mass in the left 
lobe during the first week of life. The marked change in 
vascular supply has even caused infarcts to occur, (54) 
Moreover, these same authors have also observed that the 
ductus venosus remains patent for a variable length of 
time and thus provides a shunt around the liver. (52-54) 
Such a shunt and/or the previously described hypoxemic 
stress might lead to decreased liver function over the 
first week to ten days of life. While these changes 
undoubtedly do play a role in producing neonatal jaundice, 
their exact contribution remains difficult to evaluate. 
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e) Enterohepatic circulation of bilirubin 
The final step in bilirubin metabolism is pigment 
excretion via the gut. While not a significant factor in 
adult metabolism, the unique situation of a sterile gut 
and high concentrations of beta-glucuronidase make this 
final stage more important in the neonate. The first 
evidence that bilirubin was reabsorbed from the gut came 
in the early 1960’s with experiments on rats. In 1961 
14 
Lester et al, showed that when free and conjugated C 
labelled bilirubin were placed in the gut of a rat, the 
label reappeared quickly in bile, (55) Their data also 
showed that the initial phase of absorption from the gut 
was more rapid for unconjugated bilirubin, and its total 
absorption appeared greater than conjugated bilirubin. 
These findings pointed up a "substantial" enterohepatic 
circulation of bilirubin. Two years later, Lester and 
Schmid, working with jj Gunn rats, found that conjugated 
bilirubin was not absorbed from the intestine, but had to 
be deconjugated before absorption. (56) They pointed out 
that "conjugation may be said to provide a barrier against 
intestinal absorption." 
Data concerning the absorption of bilirubin in the 
human soon began to accumulate. In 1962, Gilbertson et al. 
infused both conjugated and unconjugated labelled bilirubin 
into a 79 year old male who had a T-tube in his common bile 
duct. (57) They found that when free bilirubin was 
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administered intraduodenally, it was recovered from the T- 
tube within the next 48 hours. None was found as either 
urobilinogen or bilirubin in the feces. With similar 
administration of conjugated bilirubin, highly significant 
increases of labelled fecal urobilinogen were recovered. 
Lester repeated this experiment in three patients in 1963 
with similar results, (49) Brodersen and Hermann in 1963 
first drew attention to the possibility that recirculation 
of bilirubin from the gut might be a contributing factor 
to neonatal jaundice. (58) They examined one or more 
stools from 13 infants from age zero to nine days for con¬ 
jugated and unconjugated bilirubin and beta-glucuronidase 
activity. They found measurable enzyme activity as well 
as predominantly unconjugated bilirubin. Their conclusions 
were that the low degree of conjugation was due primarily 
to the combined absence of bacterial reduction and presence 
of large amounts of beta-glucuronidase. Based on the evi¬ 
dence cited above, they theorized that this lack of conju¬ 
gation would promote re-circulation of bilirubin out of 
the gut. In 1964, Ulstrom et al, fed charcoal, which had 
the capacity in vitro to bind bilirubin, to newborn infants 
beginning at four hours of age or twelve hours of age in an 
effort to interrupt this enterohepatic circulation. (59) 
They found that those infants given charcoal at four hours 
had significant decreases in the levels of serum bilirubin 
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significant decreases. They suggested that the enterohe- 
patic circulation was a significant factor in neonatal 
bilirubin retention,, and that this enterohepatic shunt was 
most critical in determining the level of serum bilirubin 
during the first few hours of life. Moreover, such a shunt, 
they pointed out, would constitute the only normal pre¬ 
natal route of exit for the slow luminal accumulation of 
bilirubin known to be present in the fetal bile. In 1968, 
Rosta et al» reported a significant relation between delayed 
meconium passage and the incidence of hyperbilirubinemia 
in 699 mature neonates, all delivered vaginally, (60) In 
1971, Poland and Odell fed a formula which contained agar 
to nine normal neonates delivered by cesarean section and 
the same formula without agar to ten matched controls, (12) 
Both groups were fed within the first 20 hours of life, 
(The authors had already shown that agar could bind biliru- 
bin in vitro.) They found that the agar fed infants had 
significantly lower levels of serum bilirubin and also 
significantly increased levels of fecal bilirubin excre¬ 
tion. Takimoto and Matsuda correlated increased amounts 
of fecal beta-glucuronidase with neonatal hyperbilirubinemia 
in a series of 5^ newborns. (6l) Uncertainty still exists,, 
however, over the contribution of the enterohepatic circula¬ 
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Thus, neonatal jaundice is clearly a multi-factorial 
phenomenon. Certain factors which influence the serum bili¬ 
rubin levels in one group of infants may be less important 
in other groups. No one factor can be singled out as most 
important. Increased hemolysis and hepatic immaturity, 
while important contributing factors, must be defined and 
understood in the context of a wide range of factors which 
play varying roles in different groups of newborn infants. 
While still concerned with the size of the bilirubin load 
and the hepatocyte's ability to excrete it, recent inves¬ 
tigators have begun to focus on individual enzyme systems 
and the hepatocyte membrane, both sinusoidal and canalicu¬ 
lar. Thaler's concept that neonatal jaundice may be due 
to the different rates of maturation of the heme oxygenase 
system and the glucuronyl transferase system exemplifies 
the new emphasis. (23) Unfortunately, greater understand¬ 
ing of these more sophisticated mechanisms for neonatal 
jaundice has not yet generated new therapeutic regimens. 
In general, therapeutic concepts are still based on the 
idea that hepatic immaturity is the primary cause of neo¬ 
natal jaundice. 
3. Treatment modalities 
The three most commonly used treatment modalities, 
exchange transfusion, phototherapy, and phenobarbitone 
therapy, are based on the concept that liver immaturity 
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is the primary cause of neonatal jaundice. In exchange 
transfusion and phototherapy, iatrogenic elimination of 
bilirubin will avert bilirubin encephalopathy until the 
neonate can excrete his own bilirubin load, Phenobarbi- 
tone treatment is aimed at accelerating maturity of the 
liver enzymes. Some more recent therapeutic approaches 
have focused on more specific areas of bilirubin metabo¬ 
lism, e.g., the enterohepatic circulation, 
a) Exchange transfusion 
While exchange transfusion can lower the serum 
bilirubin dramatically, there is a significant morbidity 
and mortality associated with the procedure. This fact 
has generated disagreement about the indications for 
exchange transfusion, (62) According to some authors, 
the risk of mortality from the procedure exceeds the risk 
of bilirubin toxicity, Jablonski has put the risk at 1*5% 
for full-term infants, (63) Trolle, ©n the basis of a 
6% incidence of severe neonatal jaundice (greater than 
20 mg.%) in full-term infants and 11% in premature new¬ 
borns derived from a series of 1000 livebirths, calculated 
that 2140 full-term babies would have to be transfused in 
order to prevent athetosis in one, (64) As a result, 21 
infants would die as a complication of the exchange trans¬ 
fusion, His figures for premature neonates show that 92 
infants would have to be exchanged to prevent one case of 
athetosis, with the risk of four dying. He put the 
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mortality for exchange transfusion for premature infants 
at four per cent, and that for full-term infants at one 
to two per cent. Crosse has reported a two-year experi¬ 
ence in which 6.6 premature babies were transfused to save 
each expected case of kernicterus. (65) There were 92 
babies transfused with one death resulting from transfusion 
and five infants with spastic kernicterus, all associated 
with serum bilirubin levels exceeding 22 mg.%. Fourteen 
cases of kernicterus with ten deaths had been predicted 
on the basis of the hospital’s previous experience,, As 
experience with exchange transfusion increased, the mortal¬ 
ity from the procedure fell to zero over the following 
year. However* the possibility of developmental abnormal¬ 
ities at low serum bilirubin levels combined with signifi¬ 
cant mortality figures of exchange transfusion and the 
incidence of neonatal jaundice have motivated investigators 
to look for safer means of treating neonatal jaundice. (46, 
66) 
b) Phototherapy 
Early in 1958* the head nurse in charge of the pre¬ 
mature unit of the General Hospital, Rockford, Essex, 
England, reportedly noticed the apparent fading of the 
jaundiced color of babies’ skin when they had been left 
for a short time in sunlight. (67) She also noted that 
only those areas of skin exposed to the light showed fad¬ 
ing of yellow color. Cremer et al. studied 22 infants by 
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placing them in direct sunlight and artificial light for 
short periods of time and found that serum bilirubin fell 
markedly following light exposure* (6?) In vitro studies 
of the effect of light on bilirubin by the same workers 
showed the mechanism to be photobxidation of bilirubin* 
Investigators quickly became concerned about two possible 
complications of therapy* First* some were concerned by 
the possibility that the photooxidation products might be 
more toxic than bilirubin itself. Others were worried 
that the rapid fall in bilirubin could be due to the dis¬ 
placement of bilirubin from its albumin carrier with its 
consequent deposition in tissues. However, no evidence 
of the formation of the possibly more toxic oxidation 
product, biliverdin, during phototherapy has been found, 
(35*68) Other investigators have shown that the toxic 
effects of bilirubin are abolished both in vitro and in 
vivo if bilirubin is previously degraded by illumination 
in vitro* (69) The photooxidation products have also been 
shown not to interfere with cell growth in culture. (68) 
More recent studies have shown that the breakdown of bili- 
rubin by light is oxygen dependent, and probably involves 
formation of a singlet oxygen molecule, i.e,» molecular 
oxygen in its first excited state, (46) This process results 
in eventual cleavage of the chain of four pyrrole rings that 
constitute the bilirubin molecule into fragments which con¬ 
tain two pyrrole rings linked by a methane bridge, (46) 
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Investigating both the concerns cited above, Callahan et al. 
have recently pointed out that light converts bilirubin to 
more polar, predominantly diazonegative derivatives which 
are excreted rapidly in bile and urine without detectable 
retention in plasma, (?0) He proved this statement by 
14 
infusing C “labelled bilirubin over two to twenty-four 
hours into two infants, five and seven months old, with 
the Crigler-Najjar syndrome. Both had previously responded 
to light therapy. Plasma, urine, and bile were collected 
to explore the disposition of the labelled pigment. Approx¬ 
imately three-fourths of the eliminated isotope was recovered 
from the feces with the remaining fraction appearing in 
urine. At the conclusion of the study, virtually all the 
isotope had been recovered, Callahan pointed out that this 
complete recovery makes it improbable that phototherapy 
reduces serum bilirubin levels by means of displacement of 
pigment from its albumin carrier or through significant 
redistribution of pigment between plasma and tissues. 
While these reports suggested that light therapy 
was a technically easy, effective, and safe way to reduce 
neonatal hyperbilirubinemia, other investigators were less 
convinced. Light found most effective in treatment was 
that in the 420 to 475 nanometer region of the spectrum. 
(69) Odell has pointed out that other compounds are dis¬ 
rupted by light in this range. (71) For example, albumin, 
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the primary carrier protein of bilirubin in blood, has 
several histidine molecules which contain imidazole rings. 
When these imidazole rings are exposed to bright light, 
they are cleaved with consequent reduction in bilirubin 
binding capacity in the photooxidized albumin, (71) An 
incidental finding in a recent study of the effectiveness 
of phototherapy and albumin infusion again raised the 
question of light’s effect on albumin, (33) In comparing 
albumin levels in eight control infants with eight infants 
who had received both phototherapy and an intravenous 
infusion of 1.5 g. of albumin per kg, body weight, it was 
noted that the plasma albumin levels were not significantly 
different. Moreover, other enzymes that contain histidine, 
e.g„» phosphoglucomutase, are completely and rapidly inacti¬ 
vated by photooxidation. (71) In addition, Hakani et al, 
have pointed out that while later products of photooxida- 
tion are non-toxic and do not bind with albumin, early 
products are toxic and do bind to the carrier protein. (72) 
Besides this biochemical evidence, it has also been shown 
that phototherapy is not universally effective. It is 
relatively ineffective for rapidly rising serum bilirubin, 
and the degree of reduction of serum bilirubin varies 
among subjects. (66,69,73) 
The systemic effects of phototherapy have been 
underlined by recent evidence concerning its effect on 
the rate of hepatic excretion of bile. Ostrow, working 
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with jj Gunn rats found that most bilirubin derivatives 
excreted during phototherapy are identical with those found 
under dim lighting conditions. However, there is a markedly 
enhanced hepatic excretion of diazoreaetive material. He 
concludes, therefore, that the primary effect of photother¬ 
apy is to stimulate alternate pathways of bilirubin cata¬ 
bolism that exist normally in both humans and animals, (69) 
Thus, while phototherapy may be somewhat easier and 
safer to administer than exchange transfusion or phenobar- 
bitone and by itself is beneficial in mild cases, long-term 
controlled studies are still needed. Its systemic effects 
on enzyme and organ systems as well as on the child’s over¬ 
all developmental status need to be assessed. (66) 
c) Phenobarbitone therapy 
Catz and Yaffe in 1968 noted that administration 
of phenobarbitone to newborn mice caused a significant 
increase in the activity of the liver glucuronide conjugat¬ 
ing system for bilirubin. (?4) They also found that mice 
whose mothers had been treated with phenobarbitone while 
pregnant had a significant increase in activity in the 
same enzyme system to values which approximated those of 
a normal adult. Yaffe's results with animals led him to 
study newborns to determine, firstly, if phenobarbitone 
could prevent a rise in bilirubin in the first five days 
of life, and secondly, if phenobarbitone could lower 
already elevated levels of bilirubin between the fifth 
and tenth days, (?4) He found that in 40 full-term 
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infants (20 treated infants and 20 controls), he could 
alter the peak of the bilirubin curve from day four to day 
two. Moreover, he found that in five to ten day old 
infants, phenobarbitone therapy caused a significantly 
more rapid decline in serum bilirubin values. Trolle, in 
a study of 808 newborns with birth weights greater than 
2500 g,, found that administration of phenobarbitone to 
both mother prenatally and baby was more effective than 
just to mother or just to baby, (75) Stern et al. in 
1970 confirmed the effect of phenobarbitone on the glueu- 
ronidating capacity of treated and control infants by 
administration of salicylamide. (2) He found that pheno¬ 
barbitone treated infants had an increased glucuronide 
conjugating capacity. Yeung et al, more recently have 
shown by BSP tests that phenobarbitone treatment increased 
both uptake and excretion in a series of 20 jaundiced Chinese 
infants when matched with 20 jaundiced controls. (76) 
However, despite these encouraging data, Behrman 
and Fisher have pointed out both disadvantages and uncer¬ 
tainties concerning phenobarbitone treatment. (77) First, 
they point out there is no good evaluation of mortality 
and morbidity from the therapy. Complications of sedation, 
with slow feeding and aspiration have been observed. More¬ 
over, neonatal rats from phenobarbitone treated mothers 
have decreased growth rates, altered rates of gonadal ster¬ 
oid metabolism, and increased mortality rates. They also 
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raise the interesting question that drug-induced sedation 
in the neonatal period could interfere with neurobehavioral 
development, e.g,» imprinting. In the light of these unex¬ 
plored complications, and the estimates that 77 to 95$ of 
term infants have peak bilirubin levels of under ten mg.$» 
they feel there is little justification for pre-natal treat¬ 
ment of a term baby. In examining the current small amount 
of data concerning treatment of premature infants, they 
point out that phenobarbitone appears less effective in 
lowering serum bilirubin in this more susceptible group 
of infants. 
Recently, Yeung et al, have responded to these ques¬ 
tions. (78) Working in Hong Kong with a population in which 
up to 40$ of newborns have bilirubin levels >15 mg.%, they 
have treated 2500 jaundiced newborns with phenobarbitone 
over the last three years. By using phototherapy, they 
have been able to limit the number of newborns who required 
exchange transfusion. Sedation was the commonest side 
effect. There were also six drug rashes and three cases 
of apnea and cyanosis. In defending their mode of therapy, 
they point out that in the animal studies cited by Behrman 
and Fisher, the total dose (>45 mg./kg.) and the length 
of treatment were both far greater than those employed on 
human newborns. 
Without adequate follow-up of a large series of 
phenobarbitone treated infants, however, the arguments of 
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Behrman and Fisher legimately question the indiscriminate 
treatment of neonatal jaundice with phenobarbitone. 
d) Other treatment modalities 
Other treatment modalities have been aimed primar¬ 
ily at either the maturity of the glucuronyl transferase 
system or at the enterohepatic circulation of bilirubin. 
Serein et al. reported a series of 12 sets of twins treated 
with diethylnicotinamide, a substance which induces liver 
glucuronidating enzymes, (79) They found that 96 hours 
after starting drug administration, the treated infants 
had statistically lower serum bilirubin values, Waltman 
et al. infused ethanol (118 g.) slowly into ten pregnant 
women and found a significant lowering of their infants' 
serum bilirubin values over the first five days, when com¬ 
pared to ten controls, without maternal or neonatal com¬ 
plications. (80) No Apgar scores were reported to be <8 
at one minute. Uridine-di-phospho-glucose has also been 
used to decrease neonatal serum bilirubin, (81) No large 
series have been reported, however, for any of these 
methods. 
Others have attempted to lower serum bilirubin by 
interrupting the enterohepatic circulation of bilirubin. 
Charcoal (60), agar (12), and 1,4-disaccharolactone (82) 
(a beta-glucuronidase inhibitor) have all been tried with 
varying degrees of success. The disaccharolactone study 
was poorly designed and needs re-evaluation. The major 
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complication of the other two treatments has been poor 
weight gain during the first week of life. Again, because 
of insufficient numbers studied, definite effects, either 
beneficial or hazardous, on different groups of neonates 
cannot be adequately assessed. 
More recent studies have examined the effectiveness 
of combination therapies, specifically phenobarbitone and 
light (83,84), or light plus albumin (33), Neither combin¬ 
ation was found to be more successful than one or the other 
individual component alone. 
As the means of treatment of hyperbilirubinemia 
are being repeatedly redefined, the need for treatment is 
likewise being re-examined. Historically, proof of the 
toxicity of bilirubin in newborn infants has long been 
established. (85) More recently, factors which increase 
the infant’s susceptibility to toxicity have been identi¬ 
fied. An at-risk population is currently becoming recog¬ 
nized on the basis of developmental studies which control 
for a variety of neonatal complications. An outline of 
these developmentally based concepts in the context of 
neonatal bilirubin metabolism will now be presented, 
4. Developmental studies 
a) Toxicity of bilirubin 
The toxicity of bilirubin is influenced by a wide 
variety of factors. These factors can be divided into two 
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categoriess 1) levels of indirect serum bilirubin? and, 
2) increased susceptibility of certain infants. 
1) The level of indirect serum bilirubini The most 
dramatic cause of hyperbilirubinemia in the neonatal 
period is erythroblastosis fetalis. In 1952, Hsia et al. 
reported 229 infants with serologically proven erythro» 
blastosis fetalis. (86) He showed data which compared 
serum bilirubin levels in infants with erythroblastosis 
fetalis, premature newborns, and normal neonates. The 
values for the infants with erythroblastosis fetalis rose 
much more dramatically than those for either premature or 
normal newborns. He also showed that the height of the 
serum bilirubin, which was predominantly unconjugated, 
correlated well with the incidence of kernicterus. No 
infants with erythroblastosis fetalis who had total serum 
bilirubin values <5 mg.$ showed signs of kernicterus? 
three per cent of those with six to 15 mg.$ developed 
kernicterus? while 18$ of those between 16 and 30 rag.$» 
and 50$ in whom serum bilirubin levels were >30 mg.$ 
developed kernicterus. Unfortunately, Hsia’s data did 
not reflect maximum serum bilirubin values, because the 
serum bilirubin was not measured immediately prior to 
exchange transfusion, and duration of high bilirubin was 
not considered. Nor were the results controlled for 
gestational age of the infants. Moreover, the incidence 
of kernicterus without treatment was probably underestimated 
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because almost all of the babies had exchange transfusions. 
These data suggested, however, that the liability of bill” 
rubin to cause brain damage was correlated with the serum 
level, and other studies have confirmed this, (65) 
Researchers have also looked at the ability of bilirubin 
to gain access to the brain, Nasralla et al. to assess 
the relationship between spinal fluid bilirubin and serum 
bilirubin in 100 newborns, including 34 normal newborns, 
49 normal premature newborns (4,5 pounds or less), and 1? 
infants with erythroblastosis fetalis, (87) They found a 
positive correlation coefficient between serum and spinal 
fluid bilirubin levels. Because they felt that the 
greater fraction of neonatal serum bilirubin was uneon- 
jugated, no attempt was made to measure direct reacting 
bilirubin. These data suggested that the higher the level 
of unconjugated serum bilirubin, the greater the level of 
GSF bilirubin to which the brain is exposed. The danger 
of such exposure was suggested by in vitro experiments. 
Using a system which parallels the solubility properties 
of the intra- and extra-cellular spaces, Brodersen and 
Vind have shown that it is possible for unconjugated bili¬ 
rubin to penetrate brain cells, (88) Claireaux et al, 
confirmed these findings clinically by isolating uncon¬ 
jugated bilirubin from the brains of four infants, two 
of whom were premature by dates and two of whom had hemo¬ 
lytic disease. Their identification was based on diazo 
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reactivity, chromatographic behavior, and absorption spectra 
from the affected infants1 brains. Two of the four infants 
had seizures, but the other two had no clinical history t© 
suggest kernicterus. All four had relatively deep jaundice, 
but no serum bilirubin levels were reported. These data 
thus suggested that free bilirubin can be deposited in neo¬ 
natal brain, and its ability to do damage may be a reflec¬ 
tion of the indirect or unconjugated serum levels. (133) 
Factors besides hemolysis have been correlated with 
increased levels of unconjugated bilirubin. Prematurity 
has long been considered to predispose the neonate to 
increased serum bilirubin levels. In a study of 383 
infants, Trolle divided infants of approximately equal 
weight (2000-2500 g,) into mature and premature by gesta¬ 
tional age. (89) He excluded blood group incompatibili¬ 
ties, maternal diabetes mellitus, and heart disease, but 
not sepsis, hypothermia, and various drugs. He found 
that premature infants have a higher incidence of jaundice 
of unknown etiology than under-weight full-term infants. 
Under-weight full-term infants had an incidence and degree 
of severity of jaundice similar to mature infants who 
weighed approximately 3000 g. Unfortunately, since the 
authors did not control for certain medical complications 
of the neonatal period, (known to be correlated with 
hyperbilirubinemia), it is difficult to isolate prematur¬ 




, - :• " ' ''•'1 
, ■ . - * 
. •, • V: 
j. 
; . 
■ ■./ ■ - • . •• : •* i: - • 
• . ... * 
. , 
. 
, • • •! •, 
• - 
. . ! 
.. . > . . ' ■ •, ■ 
. . c ... :• - >„r 
. . r < . . o 
, . ' 
' 
33 
earlier study of 142 full-term newborns and 173 premature 
infants (also controlled for maternal diabetes mellitus 
and blood group incompatibilities) did not mention the 
incidence of medical complications in either group, (20) 
Their data showed that the degree of hyperbilirubinemia 
correlated with either birth weight or length of gestation, 
Harris also observed in a study of 114 premature newborns 
a reciprocal correlation between birth weight and peak 
bilirubin levels, (90) Controlled for infection and 
hemolysis, she found in addition that 2?$ of her subjects 
had bilirubin levels >15 mg.fo» and ten per cent had values 
>20 mg.^. On the basis of a review of 800 cases in the 
literature, Lucey roughly corroborated these percentages 
and called hyperbilirubinemia of prematurity "a common 
occurrence.” (91) The incidence of jaundice in premature 
infants is greater than that in normal newborns, although 
the greater incidence of complications in the former group 
often makes the data difficult to interpret. Parenthetic- 
ally, it may be noted that this kind of data gave credence 
to the belief that "liver immaturity" was one of the prim¬ 
ary causes of neonatal jaundice. 
Maternal factors have also been implicated in 
influencing higher neonatal serum bilirubin levels. 
Taylor et al, showed that when third day bilirubin values 
of 48 infants of diabetic mothers were compared with con¬ 
trols matched for gestational age (33 to 40 weeks), the 
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infants of diabetic mothers had significantly greater 
hyperbilirubinemia (p <0,005). (11) While no labelling 
studies were done, no evidence for increased hemolysis 
could be demonstrated in these infants. Earlier series 
have also noted this increased incidence of hyperbili¬ 
rubinemia without evidence of hemolysis in infants of 
diabetic mothers, (92,93) Recent data concerning the 
effects of epinephrine and glucagon on the heme oxygen¬ 
ase system make these results somewhat more intelligible, 
(23) 
Another maternal factor thought to predispose to 
increased serum bilirubin levels is breast-feeding. Sub¬ 
stances isolated from breast milk (pregnanedio1) and 
maternal serum (also thought to be a progestational 
steroid) have both been reported to be associated with 
unconjugated neonatal jaundice. Although controversial, 
some investigators feel that these substances are respons¬ 
ible for hyperbilirubinemia by inhibiting glucuronyl 
transferase in the neonate’s liver, (23,94,95) Other 
maternal factors including age, medical complications, 
duration of labor and means of delivery have been reported 
as having no effect. (20,65) The influence of race and 
sex on neonatal serum bilirubin is evident primarily in 
premature newborns. (20,96) 
The factors most convincingly correlated with an 
increased incidence of neonatal jaundice are thus 
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erythroblastosis fetalis, prematurity, and maternal dia¬ 
betes. Circulating maternal steroids (transient familial 
neonatal hyperbilirubinemia) and prenanediol in maternal 
milk are most controversial in their correlations. Any 
factor that predisposes to elevated unconjugated serum 
bilirubin levels also puts an infant at risk for biliru¬ 
bin encephalopathy. Several other factors, however, may 
increase the infant's susceptibility to bilirubin toxicity. 
2) Increased susceptibility to bilirubins Factors 
which may lead to an increased risk of bilirubin toxicity 
include a wide spectrum of neonatal problems. These 
problems can be considered in two groups* 1) those com¬ 
plications which affect the permeability of neurons and 
other tissues to bilirubin; and, 2) those which decrease 
the bilirubin binding capacity of serum, thus increasing 
the amount of freely diffusible bilirubin. 
The first category includes asphyxia, acidosis, 
hypothermia, hypoglycemia, and sepsis. (65,9?) Although 
the exact pathophysiologic mechanisms of these complica¬ 
tions have not been elucidated, they are probably related 
to injury of cells, especially neurons, with consequent 
increased permeability to bilirubin. (98) The second 
category includes oxygen treatment in premature infants 
which may increase hemoglobin degradation (99)# large 
doses of intramuscular vitamin K (65), any drugs which 
are protein bound in competition with bilirubin (e.g., 
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sulfa drugs and salicylates), hypoproteinemia, and acido¬ 
sis. (30) Any one or a combination of these factors might 
lead to marked increases in permeability to bilirubin of 
brain tissue and/or diffusibility of bilirubin. These 
complications can thus increase the risk of bilirubin tox¬ 
icity in both premature and full-term infants. Boon has 
reported 26 full-term infants, none of whom had hemolytic 
disease, who developed kernicterus. (100) At necropsy, 
all had bilirubin staining of basal ganglia, as well as 
diffuse fatty change in the liver. A large percentage 
(62%) had a history of dehydration and sepsis. Some com¬ 
bination of the diffusibility of free bilirubin and 
increased cell permeability is probably required for bili¬ 
rubin to exert its toxic effects on neonatal brain. 
From this examination of factors which influence 
neonatal bilirubin levels and susceptibility to bilirubin, 
several categories of infants emerge which must be con¬ 
sidered at special risk from bilirubin toxicity. It is 
also clear that many complications can affect either the 
maximum serum bilirubin level or the infant’s susceptibil¬ 
ity to bilirubin. The usual explanations for neonatal 
jaundice are difficult to apply to these observations. 
Attention should be directed to the effects which these 
various risk factors have on the balance between the heme 
oxygenase and glucuronyl transferase systems, or the 
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ability of the hepatocyte to clear bilirubin and its abil¬ 
ity to excrete it, or the possible change in the rate- 
limiting step from conjugation to excretion. 
The implications of these factors are only begin¬ 
ning to be understood through studies which define the 
risk to the infant’s subsequent growth and development of 
various levels of serum bilirubin, 
b) Developmental risks of hyperbilirubinemia 
Kernicterus is the extreme example of neonatal 
bilirubin toxicity. Its classical features include men¬ 
tal retardation, athetoid palsy, high frequency deafness 
or neonatal death, (101) While some researchers feel that 
physiologic hyperbilirubinemia can never cause kernicterus 
in a full-term infant (102), there are case reports of 
such occurrences, (100) Claireaux et al. examined necrop¬ 
sies of liveborn infants over a four-year period and found 
that 33 of 376 had "brain jaundice," and of those 33• nine 
had been premature infants without increased hemolysis 
(2,4^). (133) Only two had had infection or other medical 
complications. Hsia et al. found the incidence of kernic¬ 
terus in babies with erythroblastosis fetalis to be 18% 
if the serum bilirubin rose to a level between 16 and 
30 mg.%» and 50% if the serum bilirubin was >30 mg,%. (86) 
Because there is poor understanding of the factors which 
define the at-risk population for kernicterus, it is dif¬ 
ficult to find data which can be compared concerning the 
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long-term developmental effects of neonatal hyperbilirubi¬ 
nemia, especially in the full-term age group. Through 
the mid-1960"s, there were two basic viewpoints concerning 
the effects of neonatal hyperbilirubinemia on the growth 
and development of the child, 
A typical earlier investigation was that of Gerver 
et al, in 1950® (103) They matched 68 children who had 
been diagnosed as having erythroblastosis fetalis, but 
who had had neither neonatal symptoms of kernicterus nor 
gross motor difficulties, with older brothers and sisters to 
achieve a close hereditary and environmental match. Using 
the Stamford Binet intelligence test, they examined the 
children at an average age of 4.5 years and found a vari¬ 
able, widespread, and usually moderate lowering (from 
114,5 to 102.7) of intelligence in affected children. The 
authors were quick to point out, however, that any severely 
ill newborn might suffer some degree of permanent functional 
impairment of intellect, and that lowering of IQ could not 
be singled out as a specific hallmark of this disease. 
Other authors were similarly impressed by the variability 
in the neurological effects of hyperbilirubinemia. In 1948, 
after reviewing eight patients with kernicterus, Lande 
pointed out that "there is no correlation between the degree 
of jaundice or anemia during the neonatal period and the 
occurrence or degree of cerebral damage." (104) Evans, in 
1950, observed that while most of the survivors of kernic¬ 
terus developed severe, symmetrical muscular incoordination, 
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usually associated with athetosis, some patients have severe 
mental defects while many others have "impaired" intelli¬ 
gence. (105) Gerrard noted that "mental retardation is by 
no means invariable or inevitable." (106) 
Against this background of confusing evidence con¬ 
cerning the effect of hyperbilirubinemia on growth and 
development, Hsia and others established the all-or-none 
concept. Central to this idea was the hypothesis that a 
cerebral threshold of toxicity existed which could be 
assessed by the level of serum bilirubin. Both his own 
data (86) and that of other investigators tended to sup¬ 
port 20 mg.$ as the threshold for development of neurolog¬ 
ical abnormalities. Shiller and Silverman examined a 
group of 110 three-year-olds who had all been premature 
(less than 2000 g.). (107) In this sample, approximately 
one fourth had uncomplicated hyperbilirubinemia (maximum 
concentrations 18 to 22 mg.$) in the neonatal period. 
Approximately one fifth exhibited signs which were inter¬ 
preted at three years of age as either suspicious or 
definite evidence of brain damage. They were unable to 
demonstrate a significant correlation between uncomplicated 
hyperbilirubinemia in these prematurely born children and 
neurological deficit at age three years. Ose et al. showed 
that in a questionnaire follow-up of 157 patients with neo¬ 
natal hyperbilirubinemia, 90% with serum bilirubin values 
>35 mg.$ died or had cerebral palsy, while there were no 
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instances of developmental retardation when the maximum 
serum bilirubin was <20 mg(108) Wishingrad et al» 
found no difference between two groups of 50 premature 
infants each with bilirubin values >18 mg'when only 
one group had been treated by exchange transfusion, (102) 
Their follow-up at one year showed neurologic abnormali¬ 
ties in seven infants from the transfused group compared 
with six infants in the untreated group. The frequency 
of neurologic deficits was similar to that found in any 
series of low birth weight babies. They suggested that 
exchange transfusion was necessary in uncomplicated non¬ 
hemolytic hyperbilirubinemia of the premature infant only 
when unconjugated bilirubin values were >24 mg»#» 
Jablonski studied 204 full-terra infants with neonatal 
jaundice of undefined etiology, (63) Forty-five had serum 
bilirubin levels >20 mg9$, and nine had levels >25 
There were no proven cases of kernieterus. At six month 
follow-up, he found no greater incidence of neurologic 
deficit in 19 infants whose bilirubin levels rose to 20 
to 25 mg.^ than in 58 whose levels never exceeded 15 to 
20 mg.$, He therefore suggested that there was no indica¬ 
tion for exchange transfusion in full-term infants with 
jaundice of undetermined etiology until the serum bilirubin 
reached 25 mg.%9 
However, over the last two to three years, the idea 
of a threshold for bilirubin toxicity has been questioned. 
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The largest series was published by Boggs et al, in 1967, 
(109) It included 23,000 single, live-born infants unse¬ 
lected for any medical reason. Both Coombs positive and 
negative babies were included as well as those who had 
been treated by exchange transfusion. The maximum serum 
bilirubin concentration was the single most important 
variable. They noted correlations between the maximum 
recorded neonatal serum bilirubin concentration and the 
incidence of low total motor and mental scores at an 
eight month examination. The series was controlled for 
the infants’ birth weights and five minute Apgar scores 
but not for gestational age. The developmental test 
used was a standardized modification of the Bayley Scale 
of Infant Development. This examination included test 
items arranged in a scale to permit classification of a 
given infant in terms of percentiles of expected achieve¬ 
ment up to fifteen months. The results showed that the 
correlation between neonatal hyperbilirubinemia and low 
mental and motor score did not begin abruptly at 20 mg,$» 
but could be seen to rise progressively and to become 
substantial at 15 to 19 Moreover, this relationship 
was found in all birth weight groups, independent of, 
although superimposed upon the effects of low birth weight 
and/or distress at birth as measured by a low Apgar score. 
Bilirubin thus seemed to have definite neurological effects 
below 20 mg.$ at least in these short-term follow-ups. 
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More reports subsequently appeared of both low 
birth weight and full"term infants who either developed 
kernicterus or showed subsequent neurological abnormali¬ 
ties with low serum bilirubin values, and without clinical 
indications of kernicterus in the neonatal period, (.110- 
112) Gartner et al. recently examined the autopsy findings 
in a series of 14 low birth weight infants who expired 
during the third to the sixth day of life. (113) Nine of 
the 14 had pathological evidence of kernicterus, i.e., 
yellow staining of one or more areas of brain with necrosis 
of brain cells in stained areas. None had clinical signs 
of kernicterus nor hemolytic disease. Moreover, the peak 
total serum bilirubin values in the group with kernicterus 
was 9.^ to 15.6 mg.$, while in those without kernicterus, 
the values were similar, 8,8 to 17.2 mg.%, In a follow-up 
study of low birth weight infants with jaundice, Crichton 
et al. examined three groups of 30 low birth weight 
infants. (114) Each group had a different maximum serum 
bilirubin level (>20 mgt% , 11 to 19.9 mg.$, and <11 mg.$). 
After four to 11 years, they found that the mean IQ scores 
were slightly lower in the most severely jaundiced group, 
and that this same group had a significant excess of men¬ 
tally retarded (IQ <?0), The mean IQ scores of the three 
groups did not, however, significantly differ. Neither 
was there a significant difference in verbal and performance 
scores, as had also been suggested by earlier studies, (115) 
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Ackerman has suggested that two new categories be estab¬ 
lished for infants who have had increased bilirubin values? 
1) "neurological damage, definitely associated with hyper¬ 
bilirubinemia," specifically athetosis or deafness or 
other clear-cut neurological signs in the newborn periods 
2) "neurological damage, possibly associated with hyper¬ 
bilirubinemia," specifically more subtle brain damage, in 
which bilirubin may have been a factor. (116) 
Odell has recently proposed a new method to assess 
an infant’s susceptibility by testing the ability of his 
serum to bind bilirubin and thus keep it from diffusing 
into cells. (11?) A saturation index is established on 
the basis of the amount of salicylate bound by the serum 
albumin of the infant. In a study of 32 children between 
the ages of four and seven, all of whom had been jaundiced, 
14 were considered normal by psychometric testing, and 18 
* 
were classified as having brain damage. (11?) There was 
no significant correlation between the presence or absence 
of brain damage and maximum bilirubin concentration, birth 
weight, sex, presence or absence of hemolytic disease, or 
use of exchange transfusion. There was, however, a signi¬ 
ficant correlation between the presence or absence of 
brain damage and the saturation index of serum protein 
with bilirubin during the neonatal period. While large 
scale studies have not yet been reported, the saturation 
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index may be a reliable method to select infants at particu- 
lar risk from bilirubin toxicity. 
Thus9 recent developmental studies seem to indicate 
that the neurological deficits secondary to hyperbilirubine¬ 
mia in the neonatal period may be observed over a wide 
range of serum bilirubin values. The infant least likely 
to be affected is the healthy term baby. The most likely 
affected is the sick premature infant. There are no defin¬ 
ite conclusions about the level of serum bilirubin at which 
risk occurs and when treatment is indicated. Differing 
susceptibilities of different groups of infants suggest 
that different steps in neonatal bilirubin metabolism play 
varying roles in determining the height of the serum bili¬ 
rubin as well as the infant’s susceptibility to it. Studies 
must therefore be designed to examine the interaction of 
this wide variety of neonatal factors. In this way, more 
reliable identification of and treatment for at-risk 




1. Patient selection 
Infants included in this study were ten full-term 
neonates by weight, gestational age, and Dubowitz score, 
delivered by cesarean section without complicating mater- 
nal factors of diabetes mellitus or toxemia, (See Table 1) 
No mother was on any pre-natal medications except vitamins 
and diuretics. None had a prior history of Rhesus sensi¬ 
tization or jaundiced babies. The indications for section 
were either cephalo-pelvic disproportion or repeat section. 
Babies delivered by cesarean section were chosen, because 
they could be followed in the hospital for five days. The 
Apgar scores at five minutes were all eight or greater. 
No abnormalities were detected on examination, and there 
were no medical complications in the newborn period. All 
were Coombs negative. All infants were cared for in the 
well-baby nurseries or in the Newborn Special Care Unit, 
Yale-New Haven Hospital, All were given intramuscular 
vitamin K as Aquamephyton in a dose of 0,5 mg. Iron for¬ 
tified cow’s milk formula was introduced at approximately 
12 hours of life, and all infants were fed on the same 
schedule. None was breast-fed. Informed consent was 
obtained from each mother. The mother’s medical and obste¬ 
trical history was derived from an interview with her and 






2. Collection of data 
Blood samples (in heparinized capillary tubes) for 
bilirubin determinations and hematocrit were obtained for 
five successive mornings. All were analyzed within 15 
minutes of sampling. Blood grouping and Coombs test, 
daily weights, feeding and stool times were all obtained 
from normal records kept on each infant and mother. 
Stools left in diapers were collected by the nurses and 
wrapped quickly in Saran Wrap. The exposure to light was 
minimized. The time of stooling and baby’s name were 
noted on each stool. All stools were picked up within 
six hours, weighed, and were analyzed within 12 hours, 
3. Preparation of reagents 
a) Serum bilirubin* Diazo reagent — ten ml. of 
a solution of 2,5 g» of sulfanilic acid in 15 ml, of con¬ 
centrated hydrochloric acid diluted to 1000 mi. were added 
to 1 ml. of 0.5$ sodium nitrite. 
b) Stool beta-glucuronidase assays Acetate buffer 
(0.0? M acetic acid; pH 5.0) — To 800 ml. of distilled 
water was added 4,0 ml, of acetic acid. The pH of the 
mixture was titrated to 5.0 with 10% sodium hydroxide. 
The mixture was then diluted to one liter with distilled 
water. 
Glycine buffer (pH 10,4) -- 15 g. of glycine and 
11.7 g. of sodium chloride were added to ?00 ml. of dis¬ 
tilled water. The pH of the mixture was adjusted to 10.4 
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with 10$ sodium hydroxide, and diluted to one liter with 
distilled water. 
Phenolphthalein standard (Sigma Chemical no. 105-1I 
1 mg./ml. of ethanol) — 2.5 ml. of phenolphthalein stand¬ 
ard was added to 7.5 ml, acetate buffer to give a final 
concentration of phenolphthalein of 2.5 mg./lO ml. of 
solution. 
Phenolphthalein glucuronic acid (Sigma Chemical 
no. 105“^) — 5 ml. of phenolphthalein glucuronic acid 
were added to 28.3 ml. distilled water to give a final 
substrate concentration of 0.0015 M. 
c) Stool bilirubin assay: Hydrogen peroxide 
reagent -- To 200 ml, of ethanol was added 0.8 ml, of 
30$ hydrogen peroxide and 4 ml. concentrated hydrochloric 
acid. 
Fifty per cent ethanol in water 
Ascorbic acid (1 g.$ in distilled water) 
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1. Serum bilirubin 
Serum bilirubin values were run in duplicate on 
0,03 ml. aliquots of serum obtained from centrifugation 
for three minutes of four full heparinized capillary tubes 
in a Model HN Centrifuge (International Equipment Company* 
Needham Heights, Mass.). Spectrophotometrie determina¬ 
tions were carried out in a Bilirubinometer (Advanced 
Instruments. Inc., Newton Highlands, Mass,). The diazo 
reagent was made up as described by the manufacturer 
(Advanced Instruments bulleton no. B1 2-2702), Two values 
each for total and direct bilirubin were obtained, and the 
average taken. Results obtained by this method are com¬ 
parable to those obtained when the standard Evelyn and 
Malloy technique is used. (118) 
2. Hematocrit 
The hematocrit was obtained after centrifugation 
for three minutes by a Micro-capillary reader (International 
Equipment Co,, Needham Heights, Mass,), 
3. Stool beta-glucuronidase assay (119*120) 
Six 25 ml, Erlenmeyer flasks were numbered one 
through six: one and two were unknowns, three and four 
were blanks, and five and six were standard points. Into 
flasks one, two, three, four, and six, 0.9 ml. aliquots of 
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acetate buffer were pipetted. Into flask five was pipetted 
1.0 ml. of acetate buffer. Into flasks one and two were 
pipetted 0.2 ml. aliquots of 0.0015 M phenolphthalein 
glucuronic acid. One™tenth ml, of phenolphthalein standard 
solution was pipetted into flask five, and 0.2 ml. into 
flask six. The fresh, undried meconium was weighed out on 
a Mettler balance to the nearest hundredth of a g, and 
diluted one g. per 5 ml, of acetate buffer. It was homo¬ 
genized for 15 minutes in a glass homogenizing tube with 
a Teflon mallet attached to a 5000 r.p.m,, 1/18 horsepower 
electric motor. The meconium homogenate was then placed 
in a separate 25 ml. Erlenmeyer flask, and all seven 
flasks were corked and equilibrated in a water bath shaker 
at 37°C. for ten minutes. To each numbered flask was 
added 0,3 ml. of the meconium homogenate. The six flasks 
were then corked and incubated with shaking for an exact 
appropriate multiple of 30 minutes. The reaction was 
stopped with the addition of 5 ml. of glycine buffer to 
each flask. The flasks were allowed to shake for two 
minutes, then 0.2 ml. aliquots of 0.0015 M phenolphthalein 
glucuronic acid were added to flasks three and four. The 
flasks were then allowed to shake for five minutes. The 
contents of the flasks were next poured into appropriately 
labelled conical centrifuge tubes and spun in a Sorvall 
Superspeed RC2B centrifuge (Ivan Sorvall, Inc., Norwalk, 
Conn.) at 5000 r.p.m. for 15 minutes. The supernatant 
from each tube was separately decanted into matched 
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spectrophotometer (Model 6a, Coleman Instruments, Inc,, 
Maywood, Illinois), Tubes three and four were blanks and 
were first adjusted to 100% transmission. The per cent 
transmission of the two standard points, tubes five and 
six (25 mg. and 50 mg, of phenolphthalein respectively), 
were then located on a graph and a line parallel with that 
of the standard curve drawn through these points. The 
values for tubes one and two were averaged and the amount 
of phenolphthalein released determined from the line drawn 
through the two standard points. The amount of phenol™ 
phthalein produced in the reaction was then converted into 
the amount of phenolphthalein released per hour per g. of 
meconium. This conversion was based on the linearity of 
the reaction rate and the uniformity of the meconium homo¬ 
genate. Since one unit of beta-glucuronidase was defined 
as that amount of enzyme which releases one mg. of phenol¬ 
phthalein in one hour, this number represents the number 
of units of beta-glucuronidase per g. of meconium. 
4. Stool bilirubin assay 
Pour conical centrifuge tubes of 10 ml. capacity 
were labelled one through fours tube two served as a 
blank for tube one, and tube four as a blank for tube 
three. The meconium was weighed out in a glass homogeniz¬ 
ing tube on a Mettier balance to the nearest one-hundredth 
of a g., mixed with 50%> ethanol in a concentration of one 
g. per 10 ml. of ethanol solution, and homogenized for 15 
minutes. Before homogenization, the homogenizing tube was 









. I r- 
» • ‘ . » 
•i. ♦ ■» "■ v 
. f, . > - ' . . . 
. r ■■■ ' 
T , , i 
51 
wrapped in tin foil to protect the homogenate from light. 
Into tubes one and two were placed 0,5 ml, aliquots of 
meconium homogenate, into tubes three and four, 1,0 ml, 
aliquots of meconium homogenate. Tube one was then 
diluted with 1,5 ml. of 50$ ethanol, tube three with 1.0 
ml, of 50$ ethanol? tube two receives 5,5 ml, of 50$ 
ethanol, tube four 5,0 ml, of 50$ ethanol. One ml. ali¬ 
quots of 1$ ascorbic acid were pipetted into tubes two 
and four. Five ml. aliquots of reagent were added to 
tubes one and three, and the time noted. After being 
tightly sealed with rubber caps, all four tubes were 
shaken in a Rotary Evapo-Mix shaker (Buchler Instruments, 
Fort Lee, New Jersey) at room temperature for ten minutes. 
They were then allowed to stand for exactly 80 minutes at 
room temperature. All four tubes were centrifuged imme¬ 
diately at the end of 80 minutes at 5000 r,p.m. for 15 
minutes. The supernatant from each tube was decanted 
separately into matched spectrophotometer tubes. The per 
cent transmission was then read in a junior spectrophoto¬ 
meter at 660 mu. (Model 6a, Coleman Instruments, Inc,, 
Maywood, Illinois), Tube two was set at 100$ transmis¬ 
sion, and the per cent transmission for tube one recorded? 
tube four was then set at 100$ transmission, and the per 
cent transmission for tube three recorded. These per cent 
transmission values were converted to mg, of bilirubin from 
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a previously established standard curve. The completeness 
of the extraction was assessed by the fact that the amount 
of bilirubin in tube three should represent twice the 
amount in tube one. Knowing the original concentration 
of meconium (Ig./ml, solution), the concentration of bili¬ 
rubin in mg./g, of meconium could be calculated from tubes 
one and three. The average of the two values was taken 
as the final answer, 
5. Preparation of bilirubin standard (121) 
Ten mg, of bilirubin was weighed out in subdued 
light on a Mettler balance and placed in a 250 ml. Erlen- 
meyer flask. Ten ml. of 0,05 N sodium hydroxide was 
quickly added and swirled to dissolve the bilirubin. 
Eighty-nine ml. of degassed 50% ethanol was then added 
and swirled. One ml. of concentrated hydrochloric acid 
was added, and the mixture stored under nitrogen away 
from light under refrigeration. The final concentration 




1. Stool beta-glucuronidase assay 
A standard curve was first established by adding 
phenolphthalein to meconium and acetate buffer digests, 
incubating, adding glycine buffer, centrifuging, and 
plotting per cent transmission against known amount of 
phenolphthalein (see Graph 1). Each point in the stand¬ 
ard curve was run in triplicate, standard deviation was 
derived from these three values. 
To prove the accuracy and reproducibility required 
the ability to recover a known amount of enzyme, A known 
quantity (200 units) of beta-glucuronidase was therefore 
added to digests containing both meconium homogenate and 
substrate. The blank contained meconium homogenate and 
beta-glucuronidase with substrate added after incubation 
and alkalinization. Two hundred units of beta-glucuroni¬ 
dase was recovered from those digests to which enzyme was 
was added. This recovery corresponded exactly to the 
amount added. Thus, the inclusion of standard points in 
the assay allows accurate correction for interference 
created by stool pigments. 
Other parameters of the reaction were also inves¬ 
tigated, In order to establish the linearity of the 
reaction rate, the reaction was stopped at 30, 60, 90, 
' . , ’V’ 
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120, and 150 minutes, A straight line was obtained when 
per cent transmission or amount of phenolphthalein released 
were plotted versus time (see Graph 2), Authors working 
with beta-glucuronidase from other sources have shown lin¬ 
earity from 30 minutes to 20 hours, (122) In order to 
test the average uniformity of the meconium homogenate, 
increasing amounts of homogenate were placed in digests 
with substrate and incubated, (123) The straight line 
relationship obtained indicates the homogeneity of the 
meconium-acetate buffer mixture (Graph 3), Other authors 
have reported inhibition ©f the enzyme from both meconium 
and other sources by the sugar 1,4-disaccharolactone, 
(123-125) The enzyme was strikingly inhibited by this 
sugar in this assay system (see Table 2), Similar t© the 
findings of other investigators, the enzyme was also found 
to be stable when the meconium homogenate was frozen imme¬ 
diately after homogenization (see Table 3), (120,123) 
2, Stool bilirubin assay 
A standard curve was established by adding known, 
increasing amounts of a standard bilirubin solution to 
the assay procedure described above (see Graph 4), To 
assure the reproducibility and accuracy of the assay, 
known increasing amounts of meconium were analysed with 
and without known added quantities of bilirubin (see 
Table 4 and Graph 5). An error of no greater than eight 
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per cent was found, a figure which compares favorably with 
that of Evelyn and Malloy, (126) 
3. Clinical results 
The neonatal and maternal blood groups,, the Coombs 
test results, the birth weights, and the per cent weight 
loss of the infants are shown in Table 1. In Tables 5 and 
6 are shown the daily total serum bilirubin levels on all 
ten infants, and. the quantities of beta-glucuronidase and 
bilirubin in the first day’s stool and first stool for all 
ten infants. In Table 7 are shown the maximum serum bili¬ 
rubin of the neonate during the first five days of life, 
the change in the serum bilirubin during the first 24 hours 
of life, the maximum change in the bilirubin between the 
first day level and the highest value during the first five 
days, the ratio of the concentrations of beta-glucuronidase 
to bilirubin in the total 24 hours. 
Analysis of these data was accomplished by linear 
regression correlation from a standard program written for 
a 9100 B Hewlett Packard Calculator, Both the ratio in 
the first stool and the ratio in the first day's total 
stool were compared individually to each of the cited bili¬ 
rubin measurements, first ©n a scatter-graph, and then by 
calculation of the correlation coefficients (see Graphs 6-9). 
The ratios were always represented on the y axis, and the 
bilirubin values on the x axis. The point for each infant 
, : ' ;> J ■ ./ 
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is represented by his number from Table 1. Correlation 




1. Beta-glucuronidase assay 
Assays for beta-glucuronidase have been applied 
to an almost endless number of tissues, body fluids,, and 
experimental models. (123) These investigations have 
centered primarily around two themes. First, researchers 
have sought a correlation between increased enzyme activ¬ 
ity in tissue or blood and neoplastic lesions. (123) 
Secondly, investigators have looked at the reciprocal 
effects of steroid hormones and beta-glucuronidase in 
both sex and non-sex organs. (123) While substrates for 
the assays used in these investigations have been as 
varied as the projects, the standard assay that has 
emerged utilized phenolphthalein glucuronic acid as a 
substrate. (120) This substrate has proven especially 
valuable in impurified tissue homogenate or body fluids. 
(127) The procedure involves incubation of two digests 
of the test substance with the substrate for a time that 
depends on the amount of activity anticipated in the 
digests. The reaction is run in an appropriate acetate 
buffer. (123) The control is made up of buffer plus the 
test digest without substrate. The blank contains only 
acetate buffer, glycine buffer, and substrate, Alkalini- 
zation of the digest with glycine buffer (pH 10.4) at the 
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end of the incubation not only stops the reaction but also 
causes the free phenolphthalein to assume its maxumum stable 
color intensity, (122) At this alkaline pH, unreacted 
phenolphthalein glucuronic acid interferes minimally with 
absorption at 5^0 mu, (123) A standard curve can thus be 
established. The difference between the spectrophotometric 
reading of the blank and that of the control is added to 
the average of the two test digests, and, by using the 
standard curve, the amount of phenolphthalein released 
during the incubation can be calculated. 
The primary problem encountered in applying this 
procedure to meconium and neonatal stool is that different 
stools interfere with spectrophotometric determinations to 
widely varying degrees because of differing amounts of 
fecal pigment and proteins. This variation clearly 
restricts the ability of the assay to detect high enzyme 
activity in stools with high interference. Earlier efforts 
to overcome this problem in beta-glucuronidase assays on 
bile included addition of charcoal after incubation and 
extraction of phenolphthalein with alcohol, (128) In an 
effort to find a shorter, easier solution to this problem, 
standard curves were established for several different 
stools. Known amounts of phenolphthalein were added to 
meconium homogenates, incubated, centrifuged, and the per 
cent transmission recorded. A standard curve without 






different stools shifted the position of the standard curve 
slightly, the slopes of the curves were both identical and 
were also the same as the standard curve without meconium 
(see Graph 1), Knowing this fact, two standard points, 
1. e., known amounts of phenolphthalein plus meconium with¬ 
out substrate were included in each assay. In this way, 
correction could be made for the varying amount of inter¬ 
ference in each stool, 
2, Bilirubin assay 
A wide variety of methodologies has also evolved 
for bilirubin assays in meconium and neonatal stool, (9) 
The assay that has won widest acceptance is that of 
Evelyn and Malloy, (126) After examining the differences 
in maximum color stability generated by using different 
reagents, they concluded that a hydrogen peroxide reagent 
gave maximum color intensity and stability in the most con¬ 
venient time. They did not, however, explore differences 
in color development and disappearance with amounts of 
bilirubin greater than ten meg. Based on previous studies 
(12,18), the amount of bilirubin that was to be measured 
in the assay described above necessitated standardization 
of values greater than ten meg. In standardizing this 
higher range, it was noted that the stability of the color 
generated by the hydrogen peroxide reagent was not as 
great as that in the lower range. In an effort to observe 
the different rates of color development in varying amounts 






of bilirubin, the reagent suggested by Evelyn and Malloy 
(126) was added to three digests with widely different 
amounts of bilirubin. Using a Gilford spectrophotometer 
(Gilford Instrument Laboratories, Inc., OberXin, Ohio) 
to read per cent transmission in each digest every 15 
minutes over a four-hour period, it was found that the 
higher amounts of bilirubin took longer than an hour to 
develop maximum color intensity and stability (see Chart 
1 and 2). In order to find a reagent that would allow 
maximum color intensity and stability to develop In a 
reasonably narrow time period over the range of 10-100 meg. 
of bilirubin, the amounts of hydrochloric acid and hydrogen 
peroxide in the reagent were varied (see Chart 3), It was 
found that the Evelyn, and Malloy reagent cited In the above 
gave maximum color intensity in 90 minutes for bilirubin 
from 10-150 meg, (see Chart 3)® However, unlike Evelyn 
and Malloy*s findings for the lower range, the stability 
of the color is not long-lasting. Unless per cent trans¬ 
mission is measured at 90 minutes, the color begins to 
disappear. The importance of an exact time period for 
the reaction was thus established, 
A single extraction procedure was employed in 
this assay for two reasons. First, it was felt that a 
constant substantial percentage of the bilirubin in the 
stool was obtained by a single extraction, (121) By 
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running 0,5 ml# and 1,0 ml. aliquots of stool homogenate 
simultaneously, this assumption was assessed with each run 
and found to be reliable. Secondly, a second extraction 
would make the assay prohibitively time-consuming for 
application on a large scale basis. 
Two other problems which arose concerned the blanks 
used with each run. The first problem is that of auto¬ 
oxidation of bilirubin in the blank. Such a process limits 
the ability of the assay to detect small differences in 
amounts of bilirubin. As suggested by Odell, ascorbic acid 
was included in each blank to prevent autooxidation, (12) 
A second and more serious problem occurred when the blank, 
because of pigment and protein in the stool, became more 
opaque than the reagent tube. If such opacity developed 
in the blank tubes, values were obtained by using tube one 
as a blank for tube three. The difference in the amount 
of bilirubin in the two tubes represented the amount of 
bilirubin in 0,5 ml. of stool. The concentration of bili¬ 
rubin in stool was then calculated on the basis of this 
value. This complication was infrequent and occurred 
primarily in stools after the third day. 
Thus, by examining the problems of standardization 
of Evelyn and Malloy’s bilirubin assay in neonatal stool, 
the method was adapted and applied more accurately and 
reproducibly. 
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3. Role of enterohepatic circulation in neonatal iuandice 
As indicated in the introduction, the contribution 
of the enterohepatic circulation of bilirutin to neonatal 
jaundice in the term infant has been recognized by a variety 
of investigators since 1961. The unique neonatal circum- 
stance of a sterile gut and high concentrations of beta- 
glucuronidase make deconjugation physiologically necessary 
for bilirubin reabsorption. In the normal adult gut, the 
conjugated bilirubin is excreted into the gut lumen conju¬ 
gated with glucuronide. Because most of the small intestine 
is relatively sterile in a normal adult down to the terminal 
ileum, the conjugated bilirubin reaches the large intestine 
before it is deconjugated and/or converted to urobilinogen, 
(129»130) The reduction of bilirubin probably Is catalyzed 
by dehydrogenases of anaerobic organisms. The origin of 
the beta-glucuronidase in the neonatal gut seems to be 
mucosal rather than bacterial on the basis of its pH opti¬ 
mum, (58,61) While the enzyme has been isolated from 
almost every tissue in the body, its presence in the neo¬ 
natal gut has not been satisfactorily explained. Prelim¬ 
inary results from an investigation in our laboratory of 
stool enzyme levels in babies whose mothers receive pheno- 
barbitone show markedly increased levels of enzyme in first 
day stools. The enzyme might be originating in the liver, 
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by the phenobarbitone. (131) Alternatively, phenobarbitone 
might be inducing increased secretion of the enzyme by 
jejunal or ileal mucosal cells, (132) 
The exact site of bilirubin reabsorption is not 
clear, but the unconjugated bilirubin most probably gains 
access to the blood stream anywhere along the small or 
large bowel, not just in the terminal ileum where other 
portions of bile are also absorbed. Due to inconvenient 
and inadequate assay systems for stool bilirubin and beta- 
glucuronidase, no other available studies have correlated 
in a systematic manner enzyme to bilirubin ratios in the 
stool and the level of serum bilirubin. 
With these assays at hand, a significant correla¬ 
tion has been demonstrated between the circumstances in 
the neonatal gut which might lead to increased bilirubin 
reabsorption, the ability of the neonate to excrete bili¬ 
rubin in his stool, and the maximum serum bilirubin level. 
Expression of the ratio of the concentrations of enzyme 
to bilirubin was chosen rather than absolute amounts, 
because the stools were wrapped in diapers for significantly 
different amounts of time (15 minutes to six hours). The 
error introduced by the change in stool weight through 
absorption into the diaper was avoided by expressing the 
ratio of the concentrations. It was also felt that such 
a ratio would reflect more accurately the interaction of 
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the enzyme and bilirubin in the lumen of the gut where 
transit times, absorption of water, and other variables 
could not be controlled. 
It was found that the ratio of the concentrations 
of enzyme to bilirubin in the first day8s stool plotted 
against the maximum bilirubin level had the highest corre¬ 
lation coefficient of the combinations tried (correlation 
coefficient equal to 0,?6), This correlation was signifi¬ 
cant (p< 0,02), In order to assure a suitably symmetrical 
distribution of points along both sets ©f axes, as assumed 
by this linear regression analysis, the log of the ratio 
was plotted against the maximum bilirubin levels (see 
Graph 10). This correlation was also found to be signifi¬ 
cant with a correlation coefficient of 0.75 (p< 0,02). 
The correlation ©f the ratio of the concentrations 
of the enzyme, beta-glucuronidase, and of bilirubin in the 
stool over the first 24 hours of life with the maximum 
serum bilirubin during the first five days of life suggests 
that in the term infant, the initial circulation of biliru¬ 
bin reabsorbed from the gut contributes significantly to 
the bilirubin load. These data also suggest that any 
treatment which would reduce the enterohepatic circulation 
of bilirubin during the first 24 hours might significantly 
reduce maximum serum bilirubin levels in full-term neo¬ 
nates, Odell et al„ have devised such a treatment with 
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which they have been able to alter serum bilirubin levels 
in the first five days of life. (12) While phenobarbitone 
treatment both pre- and post-natally shifts the peak serum 
bilirubin from day four to day two, the same kind of rise 
and fall is observed as in controls. In agar fed infants, 
the rise is much flatter with no marked increased and 
decline in serum bilirubin values, but stool excretion of 
bilirubin is significantly increased. (12) These observa¬ 
tions suggest that enterohepatic circulation plays a sig¬ 
nificant role in the full-term neonate. 
The two major criticisms which might be made of 
the data presented in this study are, first, that the 
bilirubin load from both erythropoietic and non-erythro- 
poietic sources might have varied in this population of 
infants. Red blood cell survival studies might have been 
done to prove that the increase in serum bilirubin was 
not in fact a result of increased hemolysis. An effort 
was made, however, to keep the test population as homo¬ 
geneous as possible. Secondly, measurement of conjugated 
and unconjugated bilirubin in the stool was not attempted, 
primarily for technical reasons. It would have been 
interesting to see if a correlation existed between the 
amount of enzyme and the amounts of conjugated and uncon¬ 
jugated bilirubin excreted in the stool. 
The next step in studying the significance of the 
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infants. Although no large series of infants treated 
with agar has been reported, the possible efficacy of 
such therapy should be evaluated in premature infants 
and other at-risk populations, A prospective study might 
also be done whereby first day stools of normal newborns 
are analyzed, and those who appear t© have a significant 
chance of high serum bilirubin levels secondary to a large 
enterohepatic shunt be treated with agar. The ability of 
phenobarbitone both pre- and post-natally to increase 
excretion of bilirubin might also be studied, 
4, Summary 
In summary, on the basis of the correlation between 
the ratio of the concentrations of beta-glucuronidase and 
bilirubin in the first day’s stool and the maximum serum 
bilirubin during the first five days of life, the entero¬ 
hepatic circulation of bilirubin has been shown to be a 
significant cause of hyperbilirubinemia among full-term 
normal neonates 
" 
Diagram I - Feta! Bilirubin Metabolism 
'£ . 
Bilirubin Load 
Maternal Liver Enterohepatic Circu!ation 
of Biii. from gut 
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Other Conjugation Inducers 
a) Uptake - Hepatocyte membrane 
Y and Z proteins 





d) Vascular changes at birth 
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1 - M Apes. A pos. neg. 3295 1 9/9 
2-F Apos. ABpos. neg. 2820 2 8/9 
3-M Opos. 0 pos. neg. 3840 6 8/9 
4-M Opos. Opos. neg. 3635 1 7/8 
5-F B pos. Opos. neg. 3010 5 8/10 
6-F Opos. B pos. neg. 3310 7 9/9 
- 7- F A pos. Apos. neg. 2725 9 7/9 
8-F 0 pcs. Opos. neg. 3840 5 9/9 
9-M ABpos. B pos. neg. 3080 4 8/8 
10- M A po& A pos. neg. 3570 5 9/9 
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TABLE 2-Inhibition of Beta-Glucuronidase 
by 1,4-SaccharoIactone 














TABLE 3 - Stability of Beta-Glucuronidase in 
Frozen Stool Homogenate 
0 hrs. 24 hrs. 48 hrs. 72 hrs. 168 hrs. 
Units of Beta- 
Glue. per gram 
of Stool 
450 420 425 425 420 




TABLE 4 - Accuracy of the Bilirubin Assay 
mL of stool bill In bill added bill, calcu- bill, deter- % recovery 
homogenate sample (meg. (meg.) lated (meg} mined (meg.) 
.5 37 25 62 62.5 100 
1.0 74 25 99 107 108 
1.5 III 25 136 142 104 
1.75 129 25 154 162 104 




TABLE 5-Doily Total Serum Bilirubin Levels 
* 
infant no. Day! Day 2 Day 3 Day 4 Day 5 
•• 1 4.4 7.0 5.1 4.7 4.4 
2 7.3 9.0 10.5 9.3 8.7 
3 4.7 6.0 5.3 4.5 4.3 
4 3.5 4.0 3.3 2.7 3.0 
5 6.7 7.6 7.0 6.5 5.5 
6 3.5 3.6 3.5 3.4 3.1 
7 7.0 9.7 • 13.5 15.5 17.5 
8 4.3 5.3 3.5 2.0 1.0 
9 2.3 3.5 3.5 2.3 1.7 
iO 4.5 7.5 10.5 12.0 14.5 
Aii bilirubin values expressed in mg % 
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TABLE 6 - Excretion of Beta-Glucuronidase and 
Bilirubin 
Infant’s no. CB-G3 in CB-GD in CBiiiU in CBiO in 
first stool first day first stool first day 
\ 657 610 168 218 
2 2533 2533 127 127 
3 866 866 352 352 
4 316 316 250 250 
5 1291 1291 610 610 
6 266 266 165 165 
* 
7 1916 1916 45 45 
8 583 421 235 629 
9 1250 807 30 181 
10 1150 921 320 270 
CB“GD = concentration of beta-glucuronidase expressed as units 
of enzyme per gram of stool 
CBiiD = concentration of bilirubin expressed as micrograms of 




TABLE 7 - Correlation of Serum Bilirubin Values 
CB-GH 
with EbiO in Stool 
Change in bili. CB-GJ CB~G1 
Infants no. Max bili. 24 hrs. after Max change iZbilD in CbiO in 
*_first stool_in bili. first stool first day 
1 ' 7.0 2.5 2.5 3.9 2.8 
2 10.5 1.7 3.2 20.0 20.0 
3 6.0 1.3 1.3 2.5 2.5 
4 4.0 0.5 05 1.3 1.3 
5 7.6 0.9 l.l 1.9 1.9 
6 3.5 0.1 0.1 1.6 1.6 
7 17.5 2.7 10.5 42.0 42.0 
8 5.3 1.8 2.0 2.5 0.7 
9 3.5 12 1.5 41.0 4.4 
10 14.5 3.0 10.0 3.6 3.4 
All serum bilirubins expressed in mg% 
CB-GH * concentration of beta-glucuronidase expressed as units of enzyme per 
gram of stool 
Cbili3 = concentration of bilirubin expressed as micrograms of bilirubin per 















Scatter-graph 6 - CbiiiJ in First Day’s Stool vs. 
Maximum Serum Bilirubin 
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Scatter-graph 7 - LbilD in First Stool vs. 
Change in Serum Bilirubin 
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Scatter-graph 8 - CbiSiJ in Rrst Stool vs. 
Maximum Serum Bilirubin 
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Scatter-graph 9 - Child in the First Stool vs. Change in 
Serum Bilirubin in 24 hours After the 
First Stool 














Scatter-graph 10- Log CbiliJ in First Day’s Stool 
vs. Maximum Serum Bilirubin 
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